A Randomized, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 (or ABT-493/ABT-530) With and Without Ribavirin in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Failed a Prior Direct-Acting Antiviral Agent (DAA)-Containing Therapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 May 2016
At a glance
- Drugs Glecaprevir (Primary) ; Pibrentasvir (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms MAGELLAN-1
- Sponsors AbbVie
- 15 Apr 2016 According to an Abbvie media release, in part-1 of this study 50 GT1 patients were randomized, part-2 of the study is underway in patients with compensated cirrhosis and in genotypes 4-6. Additional patients were enrolled in this study and received study drug at the higher doses of the combination, which will be used in Phase 3 clinical trials
- 15 Apr 2016 According to an Abbvie media release, results based on an analysis of the intent-to-treat population from this trial presented at The International Liver Congress™ (ILC) 2016.
- 15 Apr 2016 Results published in an Abbvie Media Release.